Uncategorized - HealthQuill

The size of the human brain is getting larger and the bigger size may reduce the potential of overall age-related dementia, according to a study.

Genetic test could end antidepressant trial and error, study suggests

HQ Team November 17, 2025: For millions living with depression and anxiety, the path to effective treatment is often a long and disheartening.

by HealthQuill
November 17, 2025
0 Comments

Bionomics Limited, a clinical-stage biotechnology company announced positive outcomes for its experimental drug to treat post-traumatic stress disorder (PTSD).

Uncategorized

ADHD medication linked to lower risk of suicidal behaviour, study finds

August 14, 2025: A new study conducted by researchers at the University of Southampton in the UK and the Karolinska Institute in Sweden.

by HealthQuill
August 14, 2025
0 Comments

Bristol Myers Squibb, a New Jersey-based drugmaker, announced it has met its primary goal of improved overall survival for its investigational therapy to treat liver cancer.

Uncategorized

Bayer and Kumquat Biosciences ink $1.3 billion deal to develop cancer inhibitor

HQ Team August 13, 2025: Bayer and Kumquat Biosciences, a clinical-stage biotech, announced an exclusive global license and collaboration agreement worth $1.3 billion.

by HealthQuill
August 13, 2025
0 Comments

AbbVie Inc. will buy Capstan Therapeutics, Inc., a clinical-stage biotechnology company, for $2.1 billion in cash to acquire the latter’s investigational medicine to treat autoimmune diseases and its delivery technology.

Uncategorized

AbbVie to acquire Capstan for $2.1b, gets experimental drug, technology

HQ Team June 30, 2025: AbbVie Inc. will buy Capstan Therapeutics, Inc., a clinical-stage biotechnology company, for $2.1 billion in cash to acquire.

by HealthQuill
June 30, 2025
0 Comments

Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from the US regulator.

Uncategorized

Gilead’s Yeztugo drug for HIV prevention in adults gets FDA nod

HQ Team June 19, 2025: Gilead Sciences, Inc.’s twice-yearly injectable drug for the prevention of HIV in adults and adolescents got approval from.

by HealthQuill
June 19, 2025
0 Comments

Stanford University researchers have developed a gene-editing technology, which they hope will lead to treatments for neurological diseases as well as traumatic injury.

Uncategorized

‘Mailman’ gene-editing tool carries molecule to exact ‘zip code’

HQ Team May 24, 2025: Stanford University researchers have developed a gene-editing technology, which they hope will lead to treatments for neurological diseases.

by HealthQuill
May 24, 2025
0 Comments

FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical trials showed “significant” improvement in overall survival rates.

Uncategorized

Study sees rising cancer cases in young adults; death rates remain stable

HQ Team May 8, 2025: In a surprising and concerning trend, new research from the National Institutes of Health (NIH) reveals that 14 types of cancer are.

by HealthQuill
May 8, 2025
0 Comments

Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a drug-induced liver injury that was resolved after discontinuation of the oral drug.

Uncategorized

Pfizer stops development of an investigational drug to treat obesity

HQ Team April 15, 2025: Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a.